Ann: FDA Strategy and Regulatory Update, page-575

Approximately this time last year Claude took over as MD. At that stage the share price was 1c. One year on and the share price is at exactly the same level and we have had more shares issued on market through capital raises, court settlements etc. The company had also set itself 4 big milestones to achieve by the end of the September quarter and to date only 1 was achieved. COVID has put restrictions across the board but in saying that it also put mental health in the spotlight more than ever before which I feel the company failed to capitalize on.
All in all a year with no share price growth and 1 milestone achievement without any revenue figure is a disappointing year in my opinion.